News and Trends 28 Feb 2018 Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with a checkpoint inhibitor to treat colorectal and pancreatic cancer. Notably, this is the third checkpoint inhibitor to be tested with Bavarian Nordic’s vaccine. A Phase I/II trial will evaluate the safety and efficacy of using Bavarian Nordic’s cancer vaccine CV301 in […] February 28, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance. Novo Holdings manages the assets of the Novo Nordisk Foundation, which invests money in companies that are working on scientific, humanitarian, and social projects. The company has launched a fund to develop new treatments for infections […] February 28, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 28 Feb 2018 Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease? Polish researchers tested a new variant of CRISPR/Cas9 that increases the gene-editing system’s precision in targeting specific DNA sequences, such as the gene responsible for Huntington’s disease. CRISPR/Cas9 offers a means of editing genes by essentially ‘cutting and pasting’ sequences of DNA. A group of researchers at the Institute of Bioorganic Chemistry in Poland has developed […] February 28, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way Researchers at the University of Cambridge believe that they have found the region of the brain that is responsible for pain relief, which should help future drug development efforts. Scientists at the University of Cambridge have identified the area of the brain that is responsible for pain relief, which could boost the development of alternative […] February 28, 2018 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases? Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time. A lack of financial incentive has put pharma off but biotechs are keen to step in and develop treatments and cures. Over 6,000 rare diseases affect up to 30 million people in the EU alone, which highlights […] February 28, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2018 This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy Summit Therapeutics’ treatment for the devastating disease, Duchenne muscular dystrophy, reduces inflammation, which could protect muscle fibers from damage. Summit Therapeutics focuses on the development of treatments that can help patients suffering from diseases that currently lack options. The biotech has reported Phase II results for its drug for the genetic disease, Duchenne muscular dystrophy […] February 27, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2018 Update: Deinove is About to Launch a Bacterial Anti-Aging Skincare Product Update (27/2/2018): Deinove produced the first industrial batch of its carotenoid product and plans to launch the cosmetic skincare treatment at the In-Cosmetics tradeshow in Amsterdam this coming April. The news resulted in a soaring 57% increase of Deinove’s stock price. Originally published on 19/12/2017 Deinove has set the wheels in motion as it looks […] February 27, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2018 Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical company dedicated to women’s reproductive medicine, states that current Phase III results for the drug show an increase in pregnancy rate of 32 % after […] February 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2018 DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial DBV Technologies’ candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin patch, Viaskin, as an immunotherapy for the treatment peanut, egg, and milk allergies. In a Phase II study, Viaskin Milk has desensitized children between the […] February 27, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2018 AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and efficiency of drug development. Pelago, a Karolinska Institute spin-off, studies the interactions between a drug and its target to make the drug development process faster and more efficient. The Cellular Thermal Shift Assay (CETSA) was developed by Pelago to examine the […] February 26, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2018 ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After raising €9.4M in January, ASIT Biotech has now brought the amount raised on the Euronext Brussels stock up to €13.9M. The funds will be put towards the Phase III […] February 26, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2018 This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro develops therapies targeting factors encoded by human endogenous retroviruses that are implicated in neurological and autoimmune disorders. The biotech’s drug, GNbAC1, which is being developed for multiple […] February 26, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email